NCT02186301
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02186301
Title TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy
Acronym EGFR
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Clovis Oncology, Inc.
Indications
Therapies
Age Groups: adult
Covered Countries USA | ITA | ESP | DEU

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field